Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.

You may also be interested in...



Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.

Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.

Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)

TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel